Revance Therapeutics reported $18.28M in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Aerie Pharmaceuticals AERI:US USD 29.2M 370K
ALKERMES ALKS:US USD 201.73M 16.13M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Cara Therapeutics CARA:US USD 7.76M 15.24M
Eli Lilly And LLY:US USD 5.36B 305M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Horizon Pharma HZNP:US USD 691.23M 45.03M
JAZZ PHA JAZZ:US USD 806.99M 1.68M
Johnson & Johnson JNJ:US USD 15.98B 134M
Merk MRK:US USD 11.52B 1.08B
Neurocrine Biosciences NBIX:US USD 381.8M 8.4M
Pacira Pharmaceuticals PCRX:US USD 116.79M 2M
Procter & Gamble PG:US USD 9.77B 1.05B
Revance Therapeutics RVNC:US USD 18.28M 566K
Teva Pharmaceutical Industries TEVA:US USD 1.71B 118M